J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):158-168.e7. doi: 10.1016/j.japh.2020.10.014. Epub 2020 Nov 10.
To assess community pharmacists' (CPs') awareness and uptake of evidence-based antimicrobial stewardship (AMS) strategies, attitudes toward collaboration with general practitioners (GPs), and needs to improve AMS practices.
A nationwide survey of randomly sampled community pharmacies across Australia was conducted in April-October 2019.
The response rate of CPs was 30.7% (613 of 2000) and 592 participating CPs (96.5%) described the key barriers to and facilitators of improving AMS. CPs (447 of 613, 72.9%) were familiar with AMS but felt that they would require training (468 of 612, 76.5%) and access to AMS practice guidelines (566 of 605, 93.6%). Respondents perceived that AMS programs could reduce the inappropriate use of antimicrobials (409 of 612, 66.8%) and the costs of treating infection (508 of 612, 83.0%). CPs often counseled patients (591 of 609, 97.0%) and reviewed drug interactions or allergies (569 of 607, 93.8%) before dispensing antimicrobials. Respondents less often used the national Therapeutic Guidelines: Antibiotic (274 of 602, 45.5%) or assessed guideline-compliance of prescribed antimicrobials (231 of 609, 37.9%). CPs were less likely to communicate with GPs (254 of 609, 41.8%) when an antimicrobial prescription was believed to be suboptimal and perceived that GPs are not receptive to their intervention regarding the antimicrobial choice (500 of 606, 82.6%) and dosage (416 of 606, 68.6%). Point-of-care tests (114 of 596, 19.1%) and patient information leaflets (149 of 608, 24.5%) were used uncommonly. Most respondents supported policies that could foster GP-pharmacist collaboration (560 of 606, 92.4%), limit accessibility of selected antimicrobials (420 of 604, 74.4%), and reduce repeat-dispensing of antimicrobial prescriptions (448 of 604, 74.2%). CPs faced interpersonal, interactional, structural, and resource-level barriers to collaborate with GPs for practicing AMS.
CPs are aware of the importance of sensible use of antimicrobials but have had limited training and resources to conduct AMS activities. Improving GPs' receptiveness and system structures for increased GP-CP collaboration seem to be a priority to accelerate CP-led AMS implementation. Further study is required to understand the views of stakeholders about the feasibility of implementing evidence-based GP-CP collaborative AMS approaches.
评估社区药剂师(CPs)对基于证据的抗菌药物管理(AMS)策略的认知和采用情况、与全科医生(GPs)合作的态度以及改进 AMS 实践的需求。
2019 年 4 月至 10 月,对澳大利亚各地的社区药房进行了全国性的随机抽样调查。
CPs 的回复率为 30.7%(2000 人中的 613 人),592 名参与的 CPs(96.5%)描述了改善 AMS 的主要障碍和促进因素。CPs(613 人中的 447 人,72.9%)熟悉 AMS,但认为他们需要接受培训(612 人中的 468 人,76.5%)和获得 AMS 实践指南(605 人中的 566 人,93.6%)。受访者认为 AMS 计划可以减少对抗生素的不当使用(612 人中的 409 人,66.8%)和治疗感染的成本(612 人中的 508 人,83.0%)。CPs 经常在配药前向患者提供咨询(609 人中的 591 人,97.0%)并检查药物相互作用或过敏(607 人中的 569 人,93.8%)。受访者较少使用国家治疗指南:抗生素(602 人中的 274 人,45.5%)或评估规定抗生素的指南遵从性(609 人中的 231 人,37.9%)。当抗生素处方被认为不理想时,CPs 与 GPs 沟通的可能性较小(609 人中的 254 人,41.8%),并且认为 GPs 不接受他们对选择抗生素和剂量(606 人中的 500 人,82.6%)和剂量(606 人中的 416 人,68.6%)的干预。很少使用即时检测(596 人中的 114 人,19.1%)和患者信息传单(608 人中的 149 人,24.5%)。大多数受访者支持可以促进 GP-药剂师合作的政策(606 人中的 560 人,92.4%)、限制选定抗生素的可及性(604 人中的 420 人,74.4%)和减少重复配药抗生素处方(604 人中的 448 人,74.2%)。CPs 在与 GPs 合作开展 AMS 实践方面面临人际、互动、结构和资源层面的障碍。
CPs 意识到合理使用抗生素的重要性,但在开展 AMS 活动方面接受的培训和资源有限。提高 GPs 的接受程度和系统结构,以增加 GP-CP 合作,似乎是加速 CP 主导的 AMS 实施的优先事项。需要进一步研究以了解利益相关者对实施基于证据的 GP-CP 协作 AMS 方法的可行性的看法。